Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board -- Ignore unavailable to you. Want to Upgrade?

To: downandout who wrote (1670)	7/29/2016 12:12:57 PM
From: ayeyou	1 Recommendation Recommended By downandout Read Replies (1) \| Respond to of 1728

I have not heard so much as a squeak out of BCT. Volume out of the blue looks to have some meaning but when you look at the sales one by one it is a totally random mix of houses buying and selling. Hard to put it off to leakage or some such. Pondered pulling a trade off in here but may be tough to do much in way of share volume without crushing price and thats counter productive. Last time around I was able to buy back all my shares for less than 1/2 of what I had sold them at so really I am riding freebies but I could get my costs down to negative territory with a well timed trade... Developments in these biotechs seem to just crawl along at a snails pace but their ultimate goal is a worthy one and when they succeed the rewards can be high.

To: downandout who wrote (1670)	8/12/2016 10:20:30 AM
From: ayeyou	1 Recommendation Recommended By downandout Read Replies (1) \| Respond to of 1728

Briacell arranges $1.5-million private placement 2016-08-12 08:05 MT - News Release Ms. Farrah Dean reports BRIACELL ANNOUNCES NON-BROKERED PRIVATE PLACEMENT Briacell Therapeutics Corp. intends to complete a non-brokered private placement of units of the company at a price of 20 cents per unit for aggregate gross proceeds of up to $1.5-million. Under the offering, each unit shall consist of one common share in the capital of the company and one common share purchase warrant. The warrants will be valid for 36 months following the date of closing of the offering, and each warrant will be exercisable for one common share at an exercise price of 30 cents if exercised during the initial 12 months and 35 cents if exercised during the subsequent 24 months following the date of closing of the offering. The company intends to use the proceeds from the offering toward the company's phase I/IIa clinical trial, for advancing the Briacell research and development program and companion diagnostic platform known as BriaDx, and for general corporate purposes. The offering is expected to close on or about Aug. 19, 2016, and is subject to the approval of the TSX Venture Exchange and other customary closing conditions. We seek Safe Harbor. © 2016 Canjex Publishing Ltd. All rights reserved.